FAST NEWS: Connect Biopharma Plunges Despite Positive Drug Trial Results
The latest: Connect Biopharma (CNTB.US) said on Tuesday its CBP-201 drug candidate achieved all primary and key secondary endpoints in the primary analysis population for a 16-week pivotal trial of…
RELATED ARTICLES
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
- HighTide Therapeutics places big IPO bet on “affluenza” drug
-
Everest reaches new heights on growing drug sales
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Missing the Covid boat, Junshi stumbles back to old business
1877.HK 688180.SHG
-
FAST NEWS: Simcere’s Covid drug trial shows promising results
2096.HK
Discover hidden China stock gems in our weekly newsletter